DE69812070D1 - Immununterdrückende Effekte von 8 substituierten Xanthinderivaten - Google Patents
Immununterdrückende Effekte von 8 substituierten XanthinderivatenInfo
- Publication number
- DE69812070D1 DE69812070D1 DE69812070T DE69812070T DE69812070D1 DE 69812070 D1 DE69812070 D1 DE 69812070D1 DE 69812070 T DE69812070 T DE 69812070T DE 69812070 T DE69812070 T DE 69812070T DE 69812070 D1 DE69812070 D1 DE 69812070D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted
- carbon atoms
- unsubstituted
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98201323A EP0956855B1 (de) | 1998-04-24 | 1998-04-24 | Immununterdrückende Effekte von 8 substituierten Xanthinderivaten |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69812070D1 true DE69812070D1 (de) | 2003-04-17 |
DE69812070T2 DE69812070T2 (de) | 2003-12-11 |
Family
ID=8233642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69812070T Expired - Fee Related DE69812070T2 (de) | 1998-04-24 | 1998-04-24 | Immununterdrückende Effekte von 8 substituierten Xanthinderivaten |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0956855B1 (de) |
AT (1) | ATE234099T1 (de) |
DE (1) | DE69812070T2 (de) |
DK (1) | DK0956855T3 (de) |
ES (1) | ES2189079T3 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110922363A (zh) * | 2019-12-28 | 2020-03-27 | 新华制药(寿光)有限公司 | 一种紫脲酸连续化生产工艺 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533464A (ja) * | 1998-12-28 | 2002-10-08 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | プテリジン誘導体の免疫抑制作用 |
US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
AU2002359365B2 (en) | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7205403B2 (en) * | 2002-02-01 | 2007-04-17 | King Pharmaceuticals Research And Development, Inc. | 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
DE60322748D1 (de) * | 2003-05-06 | 2008-09-18 | Cv Therapeutics Inc | Xanthinderivate als a2b-adenosinrezeptorantagonisten |
AU2011202523B2 (en) * | 2003-11-21 | 2013-05-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
EP1835934A4 (de) | 2004-12-23 | 2010-07-28 | Deciphera Pharmaceuticals Llc | Enzymmodulatoren und behandlungen |
WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
AU2008242767A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
BRPI0920765A2 (pt) | 2008-10-29 | 2015-08-18 | Deciphera Pharmaceuticals Llc | Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
AU2015330490B2 (en) | 2014-10-09 | 2018-08-09 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
CN105566324B (zh) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
KR101756050B1 (ko) | 2015-03-04 | 2017-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
CN110041330B (zh) * | 2018-01-16 | 2020-08-11 | 新发药业有限公司 | 一种伊曲茶碱的环保制备方法 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
RS65058B1 (sr) | 2019-12-30 | 2024-02-29 | Deciphera Pharmaceuticals Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primene |
BR112022013169A2 (pt) | 2019-12-30 | 2022-09-13 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0490181A1 (de) * | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Verwendung von Xanthinen zur Herstellung eines Medikaments mit immunsuppressiver Wirkung |
WO1996036638A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
-
1998
- 1998-04-24 DE DE69812070T patent/DE69812070T2/de not_active Expired - Fee Related
- 1998-04-24 ES ES98201323T patent/ES2189079T3/es not_active Expired - Lifetime
- 1998-04-24 DK DK98201323T patent/DK0956855T3/da active
- 1998-04-24 EP EP98201323A patent/EP0956855B1/de not_active Expired - Lifetime
- 1998-04-24 AT AT98201323T patent/ATE234099T1/de not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110922363A (zh) * | 2019-12-28 | 2020-03-27 | 新华制药(寿光)有限公司 | 一种紫脲酸连续化生产工艺 |
Also Published As
Publication number | Publication date |
---|---|
ES2189079T3 (es) | 2003-07-01 |
EP0956855A1 (de) | 1999-11-17 |
DE69812070T2 (de) | 2003-12-11 |
ATE234099T1 (de) | 2003-03-15 |
DK0956855T3 (da) | 2003-07-14 |
EP0956855B1 (de) | 2003-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69812070D1 (de) | Immununterdrückende Effekte von 8 substituierten Xanthinderivaten | |
NO933452D0 (no) | Et terapeutisk middel for parkinson's sykdom | |
ES2082805T3 (es) | Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos. | |
ATE247654T1 (de) | Neue heterozyklische verbindungen | |
ATE52498T1 (de) | Amidderivate. | |
ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
ES2053010T3 (es) | Derivados del salicilaldehido y del acido salicilico asi como sus analogos azufrados, procedimiento para su obtencion y su empleo como herbicidas y biorreguladores. | |
PT87063A (pt) | Heterocyclic compounds and their preparation and use | |
BR1100636A (pt) | Agente terapêutico para o mal de parkinson, e, derivado da xantina | |
FR2598709B1 (fr) | Derives de l'acide quinoleinecarboxylique | |
FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
BRPI0408675A (pt) | derivados de talidomida solúveis em água | |
DK384485D0 (da) | 1,6-naphthyridinderivater med kardilaterende virkning | |
KR890009862A (ko) | N-치환 메르캅토 프로판아미드 유도체 | |
KR910000150A (ko) | 대사성 골 질환 치료제 | |
ATE222583T1 (de) | Derivate substituierter amidinonaphthylester | |
KR910700236A (ko) | 치환된 3-아자비사이클로[3,1,1]헵탄, 이의 제조방법 및 이의 용도 | |
ATE135571T1 (de) | Organogermaniumderivate enthaltende zubereitungen zur therapeutischen verwendung | |
TH31604A (th) | อนุพันธ์ของไอโซอินโดล วิธีการเตรียมและการใช้อนุพันธ์ของไอโซอินโดลให้เป็นประโยชน์ในการบำบัดรักษาโรค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |